NCI-CCC Thoracic Tumor Board Question   

If so, when and to what extent? 

If CCRT is pursued, would you move forward with durvalumab consolidation? Assume the patient with ECOG PS 0 and no co-morbidities. How might this chan...

Based on subgroup analysis, do you have a preference for cisplatin over carboplatin? 

Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients that have been...

Does your management change if symptomatic or asymptomatic?

In light of CheckMate 816 and IMpower010 and FDA approval for neoadjuvant chemo-nivolumab and adjuvant chemo-atezolizumab, how do you decide which sys...

NGS without any actionable mutations and PD-L1 TPS 15%. Would you offer chemotherapy, radiation, or immunotherapy and, if so, in what order?

Do you routinely offer post-operative adjuvant radiation in addition to chemotherapy? Are the results of the recently published negative phase II...

Is there anything to differentiate the two agents? CNS penetration reportedly with adagrasib, FDA accelerated approval has been given with sotorasib.&...

Patient has been on pembrolizumab and had two symptomatic soft tissue mass treated with radiation. 

Does the 2020 approval of Nivolumab and Ipilimumab for mNSCLC with PDL1 >1% impact your decision?

Would you consider afatinib? Afatinib has shown some activity in NRG1 fusion + patients but amplifications is unclear. 

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...

Are there any data to support a specific TKI therapy for non-T790M exon 20 mutations/insertions?

Pathology is not carcinoid or small cell.

Chemoradiation completed 1.5 years prior

SRS done to the single brain met, PD-L1 5%,  BRAF G469A mutation

The patient remains without evidence of systemic disease outside of the CNS on serial imaging. Would you continue treating with SRS as lesions appear,...

Is there an advantage to early diagnosis and intervention versus observation until the nodules are amenable to percutaneous biopsy?

Should staging and treatment decisions be made based on imaging alone?

Would you offer adjuvant TKI following ADAURA data?  Or proceed with durvalumab based on PACIFIC data?

Should fractionated EBRT be administered or can repeat SBRT be used?